05.03.2024 07:00 | IQAI | Grant of Options | RNS |
01.03.2024 08:22 | IQAI | Holding(s) in Company | RNS |
01.03.2024 08:20 | IQAI | Holding(s) in Company | RNS |
26.02.2024 07:00 | IQAI | Result of Broker Option and Total Voting Rights | RNS |
22.02.2024 14:02 | IQAI | IN BRIEF: IQ-AI shares sink on discounted placing fundraise | Alliance |
22.02.2024 07:00 | IQAI | Placing and Broker Option | RNS |
09.02.2024 13:38 | IQAI | IQ-AI subsidiary asked by FDA to resubmit and modify application | Alliance |
02.02.2024 08:56 | IQAI | IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary | Alliance |
22.01.2024 10:05 | IQAI | Holding(s) in Company | RNS |
15.01.2024 07:01 | IQAI | Director Dealings and Conversion of CLNs | RNS |
15.01.2024 07:00 | IQAI | Holding(s) in Company | RNS |
10.01.2024 11:48 | IQAI | IQ-AI falls after subsidiary notes launch of treatment access scheme | Alliance |
10.01.2024 07:00 | IQAI | IB Launching an Expanded Access Program for GaM | RNS |
19.12.2023 17:00 | IQAI | IQ-AI firm gets US FDA fast-track status for oral gallium maltolate | Alliance |
19.12.2023 14:29 | IQAI | Imaging Biometrics granted FDA “Fast-Track” | RNS |
05.12.2023 11:49 | IQAI | IQ-AI stock rises on positive interim results from glioblastoma trial | Alliance |
05.12.2023 10:58 | IQAI | IQ-AI Announces Positive Interim Phase 1 Results | RNS |
20.11.2023 13:42 | IQAI | Holding(s) in Company | RNS |
09.11.2023 11:38 | IQAI | Director Dealing and Conversion of CLNs | RNS |
08.11.2023 12:04 | IQAI | IQ-AI says Imaging Biometrics submits paediatric rare disease request | Alliance |
08.11.2023 10:59 | IQAI | Application for Pediatric Rare Disease Designation | RNS |
06.11.2023 13:02 | IQAI | Holding(s) in Company | RNS |
18.10.2023 17:11 | IQAI | IN BRIEF: IQ-AI subsidiary "central" to "landmark" brain cancer study | Alliance |
18.10.2023 14:29 | IQAI | Update Regarding Imaging Biometrics LLC | RNS |
13.10.2023 08:55 | IQAI | IB Letter to Shareholders | RNS |
09.10.2023 12:09 | IQAI | IN BRIEF: IQ-AI subsidiary wins orphan drug designation from US FDA | Alliance |
09.10.2023 07:00 | IQAI | Orphan Drug Status to GaM and Total Voting Rights | RNS |
03.10.2023 11:30 | IQAI | Holding(s) in Company | RNS |
19.09.2023 14:32 | IQAI | IQ-AI shares cease trading on the OTCQB | RNS |
08.09.2023 10:25 | IQAI | IQ-AI notes vindication of subsidiary's reduced gadolinium approach | Alliance |
08.09.2023 07:00 | IQAI | Reduced Gadolinium Approach Validated' | RNS |
18.08.2023 12:17 | IQAI | IQ-AI shares jump on subsidiary's GE Healthcare deal | Alliance |
18.08.2023 12:06 | IQAI | Update on Collaboration Agreement with Mayo Clinic | RNS |
18.08.2023 11:20 | IQAI | IB & GE HealthCare Enter into Commercial Agreement | RNS |
17.08.2023 11:21 | IQAI | IQ-AI interim loss narrows amid higher revenue, lower expenses | Alliance |
17.08.2023 07:00 | IQAI | Half-year Report | RNS |
19.07.2023 10:45 | IQAI | IN BRIEF: IQ-AI subsidiary's app adopted by US medical college | Alliance |
19.07.2023 07:00 | IQAI | Imaging Biometrics Installs IB Nimble™ For MCW | Reach |
13.07.2023 11:36 | IQAI | IN BRIEF: IQ-AI granted orphan drug designation for Gallium Galtolate | Alliance |
13.07.2023 07:00 | IQAI | Orphan Drug Designation for GaM in Pediatric GBM | RNS |
27.06.2023 11:47 | IQAI | IN BRIEF: IQ-AI notes Gallium Moltate studies on tumour growth | Alliance |
27.06.2023 07:00 | IQAI | Studies Show GaM Inhibits Pediatric Tumor Growth | Reach |
23.05.2023 16:12 | XSG, UKOG, POS | TRADING UPDATES: Harworth optimistic on 2027; Plexus extends agreement | Alliance |
23.05.2023 11:02 | IQAI | Result of AGM | RNS |
23.05.2023 07:00 | IQAI | AGM Statement | RNS |
16.05.2023 15:53 | XSG, WIX, TFIF | UK shareholder meetings calendar - next 7 days | Alliance |
03.05.2023 16:14 | IQAI | Notice of AGM | RNS |
26.04.2023 14:43 | TPOU, MGCI, CREO | EARNINGS SUMMARY: Third Point Investors NAV per share drops by quarter | Alliance |
26.04.2023 07:00 | IQAI | Final Results | RNS |
28.02.2023 19:40 | MMIT, AIQ, DPA | TRADING UPDATES: AIQ revenue soars; Mobius Investment net assets drop | Alliance |
28.02.2023 15:52 | IQAI | Orphan Drug Designation Status | RNS |
13.01.2023 14:05 | IQAI | Second Price Monitoring Extn | RNS |
13.01.2023 14:00 | IQAI | Price Monitoring Extension | RNS |
13.01.2023 11:05 | IQAI | Second Price Monitoring Extn | RNS |
13.01.2023 11:00 | IQAI | Price Monitoring Extension | RNS |
11.01.2023 09:30 | IQAI, CAML, THX | CORRECT: Getech signs deal; AfriTin confirms name change | Alliance |
10.01.2023 21:34 | IQAI, CAML, THX | TRADING UPDATES: Getech signs deal; AfriTin confirms name change | Alliance |
10.01.2023 07:00 | IQAI | Letter to Shareholders | RNS |
02.12.2022 11:11 | IQAI | Holding in Company | RNS |
25.10.2022 11:00 | IQAI | Price Monitoring Extension | RNS |
30.09.2022 07:00 | IQAI | Letter to Shareholders | RNS |
26.09.2022 07:00 | IQAI | Issue of Warrants to Employees | RNS |
16.08.2022 16:40 | IQAI | Second Price Monitoring Extn | RNS |
16.08.2022 16:35 | IQAI | Price Monitoring Extension | RNS |
16.08.2022 14:39 | IQAI | IN BRIEF: IQ-AI shares plummet on widening interim loss | Alliance |
16.08.2022 09:28 | IQAI | Half-year Report | RNS |
03.08.2022 13:01 | IQAI | TR1 - Notification of Major Holdings | RNS |
11.07.2022 13:34 | IQAI | IN BRIEF: IQ-AI launches IB Clinic on Bayer Calantic platform | Alliance |
11.07.2022 07:00 | IQAI | Imaging Biometrics Announces Channel Partnership | RNS |
31.05.2022 13:26 | IQAI | IN BRIEF: IQ-AI shares rise with submission of application to US FDA | Alliance |
31.05.2022 11:05 | IQAI | Second Price Monitoring Extn | RNS |
31.05.2022 11:00 | IQAI | Price Monitoring Extension | RNS |
31.05.2022 10:44 | COBR, IQAI | SMALL-CAP WINNERS & LOSERS: IQ-AI's IB Zero G moves closer to approval | Alliance |
31.05.2022 08:00 | IQAI | Submission of FDA 510(k) Application for IB Zero G | RNS |
30.05.2022 10:47 | IQAI | Result of AGM | RNS |